2014
Clinical and Angiographic Evaluation of the Resolute Zotarolimus-Eluting Coronary Stent in Japanese Patients
Saito S, Maehara A, Vlachojannis G, Parise H, Mehran R. Clinical and Angiographic Evaluation of the Resolute Zotarolimus-Eluting Coronary Stent in Japanese Patients. Circulation Journal 2014, 79: 96. PMID: 25428602, DOI: 10.1253/circj.cj-14-0836.Peer-Reviewed Original ResearchMeSH KeywordsCombined Modality TherapyCoronary AngiographyCoronary RestenosisCoronary StenosisDrug-Eluting StentsHeart DiseasesHumansIncidenceJapanMyocardial InfarctionMyocardial RevascularizationNeointimaPlatelet Aggregation InhibitorsPostoperative ComplicationsProspective StudiesRisk FactorsSirolimusTreatment OutcomeUltrasonography, InterventionalConceptsTarget lesion revascularizationJapanese patientsR-ZESDe novo native coronary lesionsIncidence of TLRSingle-arm observational studyStent late lumen lossLong-term clinical outcomesNative coronary lesionsTarget lesion failureLate lumen lossLesion revascularizationResolute ZotarolimusLesion failureVolume obstructionAngiographic evaluationClinical outcomesCoronary lesionsLumen lossObservational studyNeointimal hyperplasiaIntravascular ultrasoundPatientsVessel studiesCoronary stentsBody Mass Index and Acute and Long-Term Outcomes After Acute Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial)
Herrmann J, Gersh B, Goldfinger J, Witzenbichler B, Guagliumi G, Dudek D, Kornowski R, Brener S, Parise H, Fahy M, McAndrew T, Stone G, Mehran R. Body Mass Index and Acute and Long-Term Outcomes After Acute Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). The American Journal Of Cardiology 2014, 114: 9-16. PMID: 24846807, DOI: 10.1016/j.amjcard.2014.03.057.Peer-Reviewed Original ResearchConceptsST-segment myocardial infarctionBody mass indexLong-term outcomesHigher body mass indexBMI quartilesMass indexMyocardial infarctionIschemia-driven target vessel revascularizationAcute Myocardial Infarction trialHigher-weight patientsLower cardiac mortalityLowest BMI quartileCardiovascular risk profileMajor bleeding eventsMyocardial Infarction trialTarget vessel revascularizationLong-term mortalityAcute cardiovascular eventsAcute myocardial infarctionLarge multinational cohortBleeding eventsHarmonizing OutcomesHospital mortalityMyocardial reinfarctionNoncardiac mortality
2011
Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials.
Kereiakes D, Smits P, Kedhi E, Parise H, Fahy M, Serruys P, Stone G. Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials. EuroIntervention 2011, 7: 74-83. PMID: 21550906, DOI: 10.4244/eijv7i1a14.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsAdverse cardiovascular eventsPaclitaxel-eluting stentsMyocardial infarctionIndependent predictorsID-TLRID-TVRCardiac deathCardiovascular eventsSPIRIT IIStent deploymentDrug-eluting stent deploymentPredictors of deathAdverse clinical outcomesCoronary artery diseaseSuperior clinical efficacyIschaemia-driven revascularisationNumber of lesionsArtery diseaseCoronary stentingClinical outcomesClinical efficacyAdverse outcomesPaclitaxel-eluting stent deploymentClinical trials